These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 36509754)

  • 1. Current progress and open challenges for applying tyrosine kinase inhibitors in osteosarcoma.
    Chen C; Shi Q; Xu J; Ren T; Huang Y; Guo W
    Cell Death Discov; 2022 Dec; 8(1):488. PubMed ID: 36509754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor Tyrosine Kinase Inhibitors for the Treatment of Recurrent and Unresectable Bone Sarcomas.
    Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
    Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
    Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
    Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
    Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
    Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
    Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis.
    Zhang Z; Zhao Y; Lu F; Hou X; Ma Y; Luo F; Zeng K; Zhao S; Zhang Y; Zhou T; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Ann Transl Med; 2019 Sep; 7(18):452. PubMed ID: 31700888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.
    Ke Q; Xin F; Fang H; Zeng Y; Wang L; Liu J
    Front Immunol; 2022; 13():913464. PubMed ID: 35677059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.
    Yang L; Yang S; Liu Y; Li J; Hu X; Wang Y; Zhang Y; Wang Y
    Thorac Cancer; 2018 Jun; 9(6):693-698. PubMed ID: 29655198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials.
    Wang H; Wang H; Yu Z; Liu H
    Onco Targets Ther; 2018; 11():5195-5201. PubMed ID: 30214225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
    Tian Z; Niu X; Yao W
    Front Oncol; 2020; 10():1642. PubMed ID: 32984034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
    Zalcberg JR
    Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Molecularly Selected Patients with Non-Small Cell Lung Cancer: A Meta-Analysis of 30 Randomized Controlled Trials.
    Liu J; Sheng Z; Zhang Y; Li G
    Target Oncol; 2016 Feb; 11(1):49-58. PubMed ID: 26206590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of chemotherapy after EGFR-TKIs resistance in 191 patients with Unknow EGFR gene mutation in advanced lung adenocarcinoma].
    He P; Wang Y; Yang S; Yu S; Wang Z; Li J; Wang B; Hao X; Wang H; Hu X; Zhang X; Shi Y
    Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):529-34. PubMed ID: 24113006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer.
    Vavalà T; Mariniello A; Novello S
    Transl Cancer Res; 2019 Jan; 8(Suppl 1):S48-S54. PubMed ID: 35117063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer.
    Tripathi SK; Pandey K; Rengasamy KRR; Biswal BK
    Med Res Rev; 2020 Nov; 40(6):2132-2176. PubMed ID: 32596830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall Treatment Strategy for Patients With Metastatic NSCLC With Activating EGFR Mutations.
    Hayashi H; Nadal E; Gray JE; Ardizzoni A; Caria N; Puri T; Grohe C
    Clin Lung Cancer; 2022 Jan; 23(1):e69-e82. PubMed ID: 34865963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma.
    Giordano F; Vaira V; Cortinovis D; Bonomo S; Goedmakers J; Brena F; Cialdella A; Ianzano L; Forno I; Cerrito MG; Giovannoni R; Ferri GL; Tasciotti E; Vicent S; Damarco F; Bosari S; Lavitrano M; Grassilli E
    J Exp Clin Cancer Res; 2019 Jun; 38(1):260. PubMed ID: 31200752
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.
    Yang Y; Li S; Wang Y; Zhao Y; Li Q
    Signal Transduct Target Ther; 2022 Sep; 7(1):329. PubMed ID: 36115852
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.